---
document_datetime: 2025-12-02 06:01:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sixmo.html
document_name: sixmo.html
version: success
processing_time: 0.1060304
conversion_datetime: 2025-12-29 20:07:56.511592
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sixmo

[RSS](/en/individual-human-medicine.xml/67214)

##### Withdrawn

This medicine's authorisation has been withdrawn

buprenorphine Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sixmo](#news-on)
- [More information on Sixmo](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 19 June the European Commission withdrew the marketing authorisation for the implant Sixmo (buprenorphine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, L. Molteni &amp; C. dei Fratelli Alitti Societa di Esercizio S.p.A., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Sixmo was granted marketing authorisation in the EU on 20 June 2019 for substitution treatment for opioid dependence in clinically stable adults who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2024.

Patients currently receiving treatment with Sixmo should have their implant removed at the end of the cycle and should be transitioned back to their previous sublingual buprenorphine dose to ensure continued treatment in accordance with the recommendations already included in the approved SmPC of the product.

Several therapeutic alternatives are also available, as either buprenorphine alone or buprenorphine in combination with naloxone, in different pharmaceutical forms.

Sixmo : EPAR - Overview

Reference Number: EMA/251834/2019

English (EN) (91.16 KB - PDF)

**First published:** 02/07/2019

**Last updated:** 14/08/2025

[View](/en/documents/overview/sixmo-epar-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-898)

български (BG) (121.88 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/bg/documents/overview/sixmo-epar-overview_bg.pdf)

español (ES) (90.27 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/es/documents/overview/sixmo-epar-overview_es.pdf)

čeština (CS) (116.96 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/cs/documents/overview/sixmo-epar-overview_cs.pdf)

dansk (DA) (89.54 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/da/documents/overview/sixmo-epar-overview_da.pdf)

Deutsch (DE) (91.13 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/de/documents/overview/sixmo-epar-overview_de.pdf)

eesti keel (ET) (87.14 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/et/documents/overview/sixmo-epar-overview_et.pdf)

ελληνικά (EL) (128.1 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/el/documents/overview/sixmo-epar-overview_el.pdf)

français (FR) (90.59 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/fr/documents/overview/sixmo-epar-overview_fr.pdf)

hrvatski (HR) (111.4 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/hr/documents/overview/sixmo-epar-overview_hr.pdf)

italiano (IT) (89.32 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/it/documents/overview/sixmo-epar-overview_it.pdf)

latviešu valoda (LV) (123.46 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/lv/documents/overview/sixmo-epar-overview_lv.pdf)

lietuvių kalba (LT) (113.7 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/lt/documents/overview/sixmo-epar-overview_lt.pdf)

magyar (HU) (110.55 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/hu/documents/overview/sixmo-epar-overview_hu.pdf)

Malti (MT) (117.08 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/mt/documents/overview/sixmo-epar-overview_mt.pdf)

Nederlands (NL) (89.73 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/nl/documents/overview/sixmo-epar-overview_nl.pdf)

polski (PL) (116.43 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/pl/documents/overview/sixmo-epar-overview_pl.pdf)

português (PT) (90.39 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/pt/documents/overview/sixmo-epar-overview_pt.pdf)

română (RO) (119.44 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/ro/documents/overview/sixmo-epar-overview_ro.pdf)

slovenčina (SK) (115.54 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/sk/documents/overview/sixmo-epar-overview_sk.pdf)

slovenščina (SL) (109.46 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/sl/documents/overview/sixmo-epar-overview_sl.pdf)

Suomi (FI) (89.03 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/fi/documents/overview/sixmo-epar-overview_fi.pdf)

svenska (SV) (89.77 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/sv/documents/overview/sixmo-epar-overview_sv.pdf)

Sixmo : EPAR - Risk-management-plan summary

English (EN) (128.2 KB - PDF)

**First published:** 02/07/2019

**Last updated:** 14/08/2025

[View](/en/documents/rmp-summary/sixmo-epar-risk-management-plan-summary_en.pdf)

## Product information

Sixmo : EPAR - Product information

English (EN) (1.02 MB - PDF)

**First published:** 02/07/2019

**Last updated:** 14/08/2025

[View](/en/documents/product-information/sixmo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-803)

български (BG) (1.2 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/bg/documents/product-information/sixmo-epar-product-information_bg.pdf)

español (ES) (1.04 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/es/documents/product-information/sixmo-epar-product-information_es.pdf)

čeština (CS) (1.16 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/cs/documents/product-information/sixmo-epar-product-information_cs.pdf)

dansk (DA) (1.03 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/da/documents/product-information/sixmo-epar-product-information_da.pdf)

Deutsch (DE) (1.06 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/de/documents/product-information/sixmo-epar-product-information_de.pdf)

eesti keel (ET) (1.03 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/et/documents/product-information/sixmo-epar-product-information_et.pdf)

ελληνικά (EL) (1.17 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/el/documents/product-information/sixmo-epar-product-information_el.pdf)

français (FR) (1.01 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/fr/documents/product-information/sixmo-epar-product-information_fr.pdf)

hrvatski (HR) (1.13 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/hr/documents/product-information/sixmo-epar-product-information_hr.pdf)

íslenska (IS) (1.05 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/is/documents/product-information/sixmo-epar-product-information_is.pdf)

italiano (IT) (1.06 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/it/documents/product-information/sixmo-epar-product-information_it.pdf)

latviešu valoda (LV) (894.17 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/lv/documents/product-information/sixmo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.15 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/lt/documents/product-information/sixmo-epar-product-information_lt.pdf)

magyar (HU) (1.15 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/hu/documents/product-information/sixmo-epar-product-information_hu.pdf)

Malti (MT) (1.18 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/mt/documents/product-information/sixmo-epar-product-information_mt.pdf)

Nederlands (NL) (1.04 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/nl/documents/product-information/sixmo-epar-product-information_nl.pdf)

norsk (NO) (1.14 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/no/documents/product-information/sixmo-epar-product-information_no.pdf)

polski (PL) (1.22 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/pl/documents/product-information/sixmo-epar-product-information_pl.pdf)

português (PT) (1.06 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/pt/documents/product-information/sixmo-epar-product-information_pt.pdf)

română (RO) (1.16 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/ro/documents/product-information/sixmo-epar-product-information_ro.pdf)

slovenčina (SK) (1.13 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/sk/documents/product-information/sixmo-epar-product-information_sk.pdf)

slovenščina (SL) (1.1 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/sl/documents/product-information/sixmo-epar-product-information_sl.pdf)

Suomi (FI) (1.04 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/fi/documents/product-information/sixmo-epar-product-information_fi.pdf)

svenska (SV) (1.03 MB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/sv/documents/product-information/sixmo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000273813 23/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sixmo : EPAR - All authorised presentations

English (EN) (29.49 KB - PDF)

**First published:** 02/07/2019

**Last updated:** 14/08/2025

[View](/en/documents/all-authorised-presentations/sixmo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-66)

български (BG) (52.24 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/bg/media/44973)

español (ES) (29.81 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/es/media/44973)

čeština (CS) (44.65 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/cs/media/44973)

dansk (DA) (29.91 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/da/media/44973)

Deutsch (DE) (29.7 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/de/media/44973)

eesti keel (ET) (29.82 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/et/media/44973)

ελληνικά (EL) (53.64 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/el/media/44973)

français (FR) (29.7 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/fr/media/44973)

hrvatski (HR) (44.4 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/hr/media/44973)

íslenska (IS) (29.71 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/is/media/44973)

italiano (IT) (29.63 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/it/media/44973)

latviešu valoda (LV) (45.63 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/lv/media/44973)

lietuvių kalba (LT) (46.34 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/lt/media/44973)

magyar (HU) (37.04 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/hu/media/44973)

Malti (MT) (46.24 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/mt/media/44973)

Nederlands (NL) (29.51 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/nl/media/44973)

norsk (NO) (29.59 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/no/media/44973)

polski (PL) (38.9 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/pl/media/44973)

português (PT) (29.82 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/pt/media/44973)

română (RO) (45.3 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/ro/media/44973)

slovenčina (SK) (38.17 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/sk/media/44973)

slovenščina (SL) (43.06 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/sl/media/44973)

Suomi (FI) (29.58 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/fi/media/44973)

svenska (SV) (29.67 KB - PDF)

**First published:**

02/07/2019

**Last updated:**

14/08/2025

[View](/sv/media/44973)

## Product details

Name of medicine Sixmo Active substance buprenorphine hydrochloride International non-proprietary name (INN) or common name buprenorphine Therapeutic area (MeSH) Opioid-Related Disorders Anatomical therapeutic chemical (ATC) code N07BC01

### Pharmacotherapeutic group

Other nervous system drugs

### Therapeutic indication

Sixmo is indicated for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.

## Authorisation details

EMA product number EMEA/H/C/004743 Marketing authorisation holder

L. Molteni &amp; C. dei Fratelli Alitti Società di Esercizio S.p.A.

Strada Statale 67

Opinion adopted 26/04/2019 Marketing authorisation issued 19/06/2019 Withdrawal of marketing authorisation 19/06/2025 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sixmo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (167.55 KB - PDF)

**First published:** 23/10/2020

**Last updated:** 14/08/2025

[View](/en/documents/procedural-steps-after/sixmo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf-0)

## Initial marketing authorisation documents

Sixmo : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/266482/2019

English (EN) (3.09 MB - PDF)

**First published:** 02/07/2019

**Last updated:** 14/08/2025

[View](/en/documents/assessment-report/sixmo-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Sixmo

Adopted

Reference Number: EMA/CHMP/215656/2019

English (EN) (90.34 KB - PDF)

**First published:** 26/04/2019

**Last updated:** 14/08/2025

[View](/en/documents/smop-initial/chmp-summary-opinion-sixmo_en.pdf)

#### News on Sixmo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019) 26/04/2019

[New long-lasting implant to treat opioid dependence](/en/news/new-long-lasting-implant-treat-opioid-dependence) 26/04/2019

#### More information on Sixmo

- [A Retrospective and prospective, obsErvational (non-interventional), post-authorization Safety cohort sTudy to evaluate the incidence of the breAkages and insertion/Removal complications of buprenorphine implants in rouTine clinical care (RE-START) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000092)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 14/08/2025

## Share this page

[Back to top](#main-content)